Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients

• Published in: The oncologist (Dayton, Ohio) Vol. 21; no. 5; pp. 600 - 607
• Main Authors: Brandi, Giovanni, Deserti, Marzia, Vasuri, Francesco, Farioli, Andrea, Degiovanni, Alessio, Palloni, Andrea, Frega, Giorgio, Barbera, Maria A., Lorenzo, Stefania, Garajova, Ingrid, Di Marco, Mariacristina, Pinna, Antonio D., Cescon, Matteo, Cucchetti, Alessandro, Ercolani, Giorgio, D'Errico‐Grigioni, Antonietta, Pantaleo, Maria A., Biasco, Guido, Tavolari, Simona, Aprile, Guiseppe, Cereda, Stefano, Fornaro, Lorenzo, Leone, Francesco, Lonardi, Sara, Santini, Daniele, Silvestris, Nicola, Vasile, Enrico
• Format: Journal Article
• Language: English
• Published: Durham, NC, USA AlphaMed Press 01.05.2016
• Subjects: Adjuvant gemcitabine; Aged; Antimetabolites, Antineoplastic - therapeutic use; Bile Duct Neoplasms - chemistry; Bile Duct Neoplasms - drug therapy; Bile Duct Neoplasms - mortality; Bile Duct Neoplasms - surgery; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cholangiocarcinoma - chemistry; Cholangiocarcinoma - drug therapy; Cholangiocarcinoma - mortality; Cholangiocarcinoma - surgery; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; Disease-Free Survival; Equilibrative Nucleoside Transporter 1 - analysis; Female; Hepatobiliary; Human equilibrative nucleoside transporter 1; Humans; Male; Middle Aged; Predictive biomarkers of response to chemotherapy; Human equilibrative nucleoside transporter 1; Predictive biomarkers of response to chemotherapy; Adjuvant gemcitabine; Cholangiocarcinoma

Background. The use of gemcitabine as an adjuvant modality for cholangiocarcinoma (CC) is increasing, but limited data are available on predictive biomarkers of response. Human equilibrative nucleoside transporter 1 (hENT‐1) is the major transporter involved in gemcitabine intracellular uptake. This...